Delaware
(State
or other jurisdiction of
incorporation
or organization)
|
13-4087132
(I.R.S.
Employer
Identification
No.)
|
750
Lexington Avenue
New
York, New York
(Address
of principal executive offices)
|
10022
(Zip
Code)
|
Large
accelerated filer £
|
Accelerated
filer x
|
Non-accelerated
filer £
|
Exhibit
|
|||
Number
|
Exhibit
Description
|
||
|
|
||
10.21*
|
License
Agreement between Keryx Biopharmaceuticals, Inc. and Panion & BF
Biotech, Inc.
dated as of November 7, 2005.
|
||
31.1
|
Certification
of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a),
as
adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 17, 2006.
|
||
31.2
|
Certification
of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a),
as
adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 17, 2006.
|
||
_______
*
Confidential treatment has been requested with respect to the omitted
portions of this exhibit.
|
KERYX
BIOPHARMACEUTICALS, INC.
|
||
By:
|
/s/
Ronald C. Renaud, Jr.
|
|
Ronald
C. Renaud, Jr.
Senior
Vice President, Chief Financial Officer,
Secretary
and Treasurer
|
||
Exhibit
|
|||
Number
|
Exhibit
Description
|
||
|
|
||
10.21*
|
License
Agreement between Keryx Biopharmaceuticals, Inc. and Panion & BF
Biotech, Inc.
dated as of November 7, 2005.
|
||
31.1
|
Certification
of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a),
as
adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 17,
2006.
|
||
31.2
|
Certification
of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a),
as
adopted pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002, dated May 17,
2006.
|
||
__________
*
Confidential treatment has been requested with respect to the
omitted portions of this exhibit.
|